此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

比利时肺功能研究 (AIRCAST)

2026年10月15日 更新者:Wim Janssens、KU Leuven

比利时肺功能研究:个性化纵向肺功能分析作为疾病进展标志物

Currently, it remains unclear how to manage serial lung function measurements in a clinical setting. The investigators aimed to tackle this problem by developing a machine learning (ML) model that can accurately predict population and individual lung function trajectories. These predictions would enable the investigators to identify positive or negative deviations, thereby revealing unexpected disease patterns.

A prospective validation is needed that includes data on mortality, hospitalisations, emergency-room visits and patient-reported outcomes. Within this study, the goal is to validate the ML model with the data collected from this observational study.

研究概览

地位

招聘中

详细说明

The objective of this study is to explore the clinical value of models predicting longitudinal lung function patterns in individuals with chronic respiratory diseases across Belgium.

  1. The investigators will assess the accuracy of individualised lung function prediction models in a multicentre lung function dataset with prospective clinical and lung function follow-up.
  2. The investigators will evaluate important health outcomes, step-up in care, patient-reported outcomes in individuals identified with an expected and unexpected observed trajectory as compared to the predicted population and individualised trajectory.

The hypothesis is that patients with an unexpected decline in lung function will have worse health outcomes, such as a higher mortality rate and more hospitalisations, compared to patients with an expected lung function pattern. The investigators hypothesise to observe better health outcomes and lower mortality rates in patients with an unexpectedly positive lung function evolution compared to patients with an expected negative lung function pattern.

Individuals will be recruited from 4 Belgian Hospitals (UZ Leuven, UZ Antwerpen, AZ Delta, ZOL Genk). Based on the annual rate of pulmonary function testing in these hospitals, a sample size of 1.000 participants per centre is anticipated within one year of inclusions, resulting in a total sample size of 4.000 patients.

All available historical lung function data of included individuals will be retrieved from the individuals medical file. Additionally, the individual will be prospectively followed for 2 years where all lung function data will be collected.

研究类型

观察性的

注册 (估计的)

5000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Edegem、比利时、2650
        • 招聘中
        • UZ Antwerpen
        • 接触:
        • 首席研究员:
          • Therese Lapperre
        • 副研究员:
          • Kevin De Soomer
      • Genk、比利时、3600
        • 招聘中
        • Ziekenhuis Oost-Limburg
        • 接触:
        • 首席研究员:
          • David Ruttens
        • 副研究员:
          • Maarten Criel
      • Ghent、比利时
        • 招聘中
        • UZ Gent
        • 首席研究员:
          • Eric Derom
        • 接触:
        • 副研究员:
          • Lies Lahousse
      • Leuven、比利时、3000
        • 招聘中
        • UZ Leuven
        • 首席研究员:
          • Wim Janssens
        • 接触:
      • Roeselare、比利时、8800
        • 招聘中
        • AZ Delta
        • 首席研究员:
          • Ingel Demedts
        • 接触:
        • 副研究员:
          • Bernard Bouckaert

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Chronic respiratory diseases

描述

Inclusion Criteria:

  • Above 18 years old
  • Diagnosed with a chronic respiratory disease and followed up in one of the participating Belgian hospitals
  • Performed a complete lung function test (spirometry, body plethysmography and diffusion capacity) at baseline
  • Have at least 3 historical spirometry measurements over a minimal time window of 2 years prior to inclusion
  • Planned routine follow-up within standard clinical care in one of the participating hospitals

Exclusion Criteria:

  • Patients who have had a lung transplantation
  • Patients not being able to give consent to participate

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Accuracy of lung function predictions (FEV1)
大体时间:at 1 and 2-year follow-up

Proportion of correct and incorrect FEV1 predictions compared to the observed measure

at 1 and 2-year follow-up

次要结果测量

结果测量
措施说明
大体时间
Differences in clinical outcomes between correct and incorrect lung function predictions (FEV1)
大体时间:at 1 and 2-year follow-up

Differences between patients with correct and incorrect individual lung function predictions for FEV1 on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care

at 1 and 2-year follow-up
Accuracy of lung function predictions
大体时间:at 1 and 2-year follow-up

Proportion of correct and incorrect lung function predictions (FVC, TLC, RV/TLC, DLCO) compared to the observed measure

at 1 and 2-year follow-up
Differences in clinical outcomes between correct and incorrect lung function predictions
大体时间:at 1 and 2-year follow-up

Differences between patients with correct and incorrect individual lung function predictions for FVC, TLC, RV/TLC, DLCO on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care)

at 1 and 2-year follow-up
Identifying the minimal needed to make predictions
大体时间:after 2 years

Minimal number of tests/length of follow-up required for optimal predictions

after 2 years
Performance of ML-based predictions compared to linear regression analysis
大体时间:at 1 and 2-year follow-up

Comparison of the ML-based predictions for individual and population lung function changes with predictions based on linear regression on individual historical data

at 1 and 2-year follow-up
Overall description of population
大体时间:baseline, 1 and 2-year follow-up

Sociodemographic information, health status, comorbidities, frailty, disease labels, interventions and prognosis of individuals with a chronic respiratory disease

baseline, 1 and 2-year follow-up

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Wim Janssens、UZ/KU Leuven

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月25日

初级完成 (估计的)

2029年3月1日

研究完成 (估计的)

2029年3月1日

研究注册日期

首次提交

2026年2月12日

首先提交符合 QC 标准的

2026年2月12日

首次发布 (实际的)

2026年2月19日

研究记录更新

最后更新发布 (实际的)

2026年10月20日

上次提交的符合 QC 标准的更新

2026年10月15日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • S70923
  • C2M25045 (其他赠款/资助编号:Internal funding KULeuven)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅